Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...

Men with advanced prostate cancer are typically treated with androgen deprivation therapy, but most ultimately develop resistance and incurable disease (e.g. castration-resistant prostate cancer (CRPC ...

At the World Congress of Endourology and Uro-Technology, Helen Gao reviews outcomes for 106 adults with Bosniak II through IV renal cysts managed between 2010 and 2024. Surgical intervention rates ...

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and ...

Nocturia is a common symptom among adults and is often associated with disrupted sleep and diminished quality of life. In many cases, it is driven by nocturnal polyuria, an imbalance in nighttime ...

At the 2026 UCSF-UCLA PSMA Conference, Jonathan Chou reviews non-PARP DNA repair targets as radiosensitizers for radiopharmaceutical therapy, highlighting a CRISPR-Cas9 functional genomics screen ...

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...

Silke Gillessen speaks with Neeraj Agarwal about the Advanced Prostate Cancer Consensus Conference, marking its 10th anniversary edition in Lugano. Dr. Gillessen describes APCCC's focus on daily ...

We present the first metastatic castration-resistant prostate cancer (mCRPC) patient, heavily pretreated with multiple systemic and radioligand therapies, who received [212Pb]Pb-PSMA radioligand ...